MedTrace Logo

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

NCT03424122 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-08-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

Conditions

Interventions

DRUG

Parsaclisib

Parsaclisib administered orally once daily for 8 weeks followed by once weekly.

DRUG

Rituximab

Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.

DRUG

Bendamustine

Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.

DRUG

Ibrutinib

Ibrutinib administered orally once daily.

Sponsors & Collaborators

Principal Investigators

  • Peter Langmuir, MD · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2022-06-27
Completion
2022-06-27
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424122 on ClinicalTrials.gov